Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and delivering highly innovative and life-transforming therapies for patients with severe and life-threatening diseases. Patients with these diseases often have no effective treatment options and live with little hope. At Alexion, the patients we serve are at the heart of everything we do. We developed Soliris® (eculizumab), the world’s first and only approved terminal complement inhibitor, from the laboratory through regulatory approval and commercialization. Soliris was the first treatment specifically developed and approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two devastating and life-threatening ultra-rare diseases.
Alexion is investigating eculizumab as a treatment for patients with additional life-threatening rare disorders in the areas of neurology and transplant in which the inhibition of terminal complement has potential benefits for patients.
And, we are investigating other highly innovative therapeutic candidates as treatments for patients with additional life-threatening and rare conditions. These include asfotase alfa for patients with hypophosphatasia; ALXN1007, a novel anti-inflammatory antibody; and ALXN 1101, cPMP replacement therapy for patients with molybdenum cofactor deficiency Type A.
Alexion was established in New Haven, Conn. in 1992 and became a public company in 1996 (NASDAQ: ALXN). We were added to the NASDAQ-100 Index in 2011 and to the Standard & Poor's 500 Index in 2012. Our global headquarters and research operations are in Cheshire, Conn., Alexion employs nearly 2,300 people around the world with operations in place to serve patients in 50 countries. Alexion plans to move its global headquarters back to New Haven, Conn. in 2015.
Alexion Pharmaceuticals was founded in 1992 and is headquartered in New Haven, US